Syntara Limited Stock price

Equities

SNT

AU0000312480

Pharmaceuticals

End-of-day quote Australian S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.021 AUD +5.00% Intraday chart for Syntara Limited -4.55% +5.00%
Sales 2024 * 11.6M 7.56M Sales 2025 * 3.6M 2.35M Capitalization 25.07M 16.33M
Net income 2024 * -8M -5.21M Net income 2025 * -13M -8.47M EV / Sales 2024 * 1.54 x
Net cash position 2024 * 7.2M 4.69M Net cash position 2025 * 9.2M 5.99M EV / Sales 2025 * 4.41 x
P/E ratio 2024 *
-1.91 x
P/E ratio 2025 *
-2.33 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.57%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Syntara Limited

1 day+5.00%
1 week-4.55%
Current month-8.70%
1 month-8.70%
3 months-4.55%
6 months-41.67%
Current year+5.00%
More quotes
1 week
0.02
Extreme 0.02
0.02
1 month
0.02
Extreme 0.019
0.03
Current year
0.02
Extreme 0.016
0.03
1 year
0.02
Extreme 0.016
0.06
3 years
0.02
Extreme 0.016
0.15
5 years
0.02
Extreme 0.016
0.31
10 years
0.02
Extreme 0.016
0.42
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 03-03-11
Director of Finance/CFO 67 02-11-30
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Chief Executive Officer 62 03-03-11
Director of Finance/CFO 67 02-11-30
Chairman 66 17-06-06
More insiders
Date Price Change Volume
24-03-28 0.021 +5.00% 474,462
24-03-27 0.02 -4.76% 57,084
24-03-26 0.021 -4.55% 41,666
24-03-25 0.022 +4.76% 1,758,489
24-03-22 0.021 -4.55% 321,929

End-of-day quote Australian S.E., March 27, 2024

More quotes
Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Syntara Limited - Australian S.E.